Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight

被引：0
|
作者：
Ji Hye Min
Ho Yun Lee
Hoyeong Lim
Myung-Ju Ahn
Keunchil Park
Man Pyo Chung
Kyung Soo Lee
机构：
[1] Samsung Medical Center,Deparment of Radiology
[2] Sungkyunkwan University School of Medicine,The Division of Hematology
[3] Samsung Medical Center,Oncology, Department of Internal Medicine
[4] Sungkyunkwan University School of Medicine,Division of Respiratory and Critical Care Medicine at the Department of Internal Medicine
[5] Samsung Medical Center,undefined
[6] Sungkyunkwan University School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 68卷
关键词：
Tyrosine kinase inhibitors; Drug-associated interstitial lung disease; Pulmonary toxicity; Gefitinib; Erlotinib; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1099 / 1109
页数：10
相关论文
共 50 条
  • [1] Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight
    Min, Ji Hye
    Lee, Ho Yun
    Lim, Hoyeong
    Ahn, Myung-Ju
    Park, Keunchil
    Chung, Man Pyo
    Lee, Kyung Soo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1099 - 1109
  • [2] The Prediction of Risk Factors of Drug-Induced Lung Complication in Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer
    Kang, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [3] EGFR TYROSINE KINASE INHIBITOR USED IN NON-SMALL CELL LUNG CANCER
    Joshi, Pooja
    Singh, Anita
    Bisht, Dheeraj
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (03): : 1033 - 1041
  • [4] COMPARISON OF RESPONSE TO METHYLPREDNISOLONE PULSE THERAPY ON DRUG-INDUCED LUNG INJURY IN PATIENTS OF NON-SMALL CELL LUNG CANCER WITH OR WITHOUT INTERSTITIAL LUNG DISEASES
    Yasuda, Yuto
    Taguchi, Yoshio
    Tanaka, Eisaku
    Hajiro, Takashi
    Hashimoto, Seishu
    Yasuda, Takehiro
    Kaji, Yusuke
    Okamori, Satoshi
    Yasuda, Ikko
    Morimoto, Chie
    Inao, Takashi
    Hamao, Nobuyoshi
    Noma, Satoshi
    RESPIROLOGY, 2015, 20 : 83 - 83
  • [5] Tyrosine Kinase Inhibitor Induced Lung Injury Masking Accelerated Repopulation of Metastatic Non-Small Cell Lung Cancer
    Reddy, V.
    Hossain, T.
    Munger, J.
    Parnia, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [6] Tyrosine kinase inhibitor Non-small cell lung cancer therapy Treatment of glioblastoma Treatment of polycystic kidney disease
    Gajdosik, Z.
    DRUGS OF THE FUTURE, 2016, 41 (06) : 353 - 359
  • [7] Tyrosine Kinase Inhibitor Induced Interstitial Lung Disease
    Abid, H.
    Siddiqui, N.
    Thirukonda, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [8] Overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Sierra, J. Rafael
    Chang, Anderson
    Moffat, Jason
    Neel, Benjamin G.
    Tsao, Ming-Sound
    CANCER RESEARCH, 2012, 72
  • [9] Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer
    Sierra, Rafael
    Chang, Anderson
    Moffat, Jason
    Neel, Benjamin G.
    Tsao, Ming-Sound
    CLINICAL CANCER RESEARCH, 2012, 18 (03)
  • [10] Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study
    Zhao, Min
    Liu, Shu
    Xie, Rui
    Zhang, Jianjun
    Li, Jiang
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (12) : 1309 - 1316
12345